Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A; LEADe Investigators. Feldman HH, et al. Among authors: demicco da. Neurology. 2010 Mar 23;74(12):956-64. doi: 10.1212/WNL.0b013e3181d6476a. Epub 2010 Mar 3. Neurology. 2010. PMID: 20200346 Clinical Trial.
Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study).
Johnson C, Waters DD, DeMicco DA, Breazna A, Bittner V, Greten H, Grundy SM, LaRosa JC. Johnson C, et al. Among authors: demicco da. Am J Cardiol. 2008 Nov 15;102(10):1312-7. doi: 10.1016/j.amjcard.2008.07.023. Epub 2008 Sep 5. Am J Cardiol. 2008. PMID: 18993147 Clinical Trial.
Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
Deedwania PC, Shepherd J, Breazna A, DeMicco DA; Treating to New Targets (TNT) Steering Committee Investigators. Deedwania PC, et al. Among authors: demicco da. Diabetes Obes Metab. 2016 Jan;18(1):56-63. doi: 10.1111/dom.12581. Diabetes Obes Metab. 2016. PMID: 26434404 Clinical Trial.
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).
Ho JE, Waters DD, Kean A, Wilson DJ, Demicco DA, Breazna A, Wun CC, Deedwania PC, Khush KK; TNT Investigators. Ho JE, et al. Among authors: demicco da. Am J Cardiol. 2012 Jun 15;109(12):1761-6. doi: 10.1016/j.amjcard.2012.02.019. Epub 2012 Mar 28. Am J Cardiol. 2012. PMID: 22459310 Free PMC article. Clinical Trial.
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Mora S, et al. Among authors: demicco da. Circulation. 2012 Apr 24;125(16):1979-87. doi: 10.1161/CIRCULATIONAHA.111.088591. Epub 2012 Mar 29. Circulation. 2012. PMID: 22461416 Free PMC article. Clinical Trial.
64 results